222 related articles for article (PubMed ID: 37284302)
1. Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis.
Lin L; Liu Y; Chen C; Wei A; Li W
Front Pharmacol; 2023; 14():1190001. PubMed ID: 37284302
[No Abstract] [Full Text] [Related]
2. Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis.
Sun Q; Sun H; Wu N; Hu Y; Zhang F; Cong X
Front Oncol; 2022; 12():976224. PubMed ID: 36185176
[TBL] [Abstract][Full Text] [Related]
3. Immune-related adverse events and their effects on survival outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Liang Y; Xu H; Liu F; Li L; Lin C; Zhang Y; Wang N; Wang L
Front Oncol; 2024; 14():1281645. PubMed ID: 38887231
[TBL] [Abstract][Full Text] [Related]
4. Association between immune-related adverse events and prognosis in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.
Ma S; Nie H; Wei C; Jin C; Wang L
Front Oncol; 2024; 14():1402017. PubMed ID: 38779082
[TBL] [Abstract][Full Text] [Related]
5. Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Zhou Y; Chen H; Tang L; Feng Y; Tao Y; Huang L; Lou N; Shi Y
Immunotherapy; 2023 Feb; 15(3):209-220. PubMed ID: 36710655
[TBL] [Abstract][Full Text] [Related]
6. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis.
Zhou X; Yao Z; Yang H; Liang N; Zhang X; Zhang F
BMC Med; 2020 Apr; 18(1):87. PubMed ID: 32306958
[TBL] [Abstract][Full Text] [Related]
7. Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis.
Wang D; Chen C; Gu Y; Lu W; Zhan P; Liu H; Lv T; Song Y; Zhang F
Front Oncol; 2021; 11():631949. PubMed ID: 33732650
[TBL] [Abstract][Full Text] [Related]
8. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.
Liang X; Chen X; Li H; Li Y
Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447
[TBL] [Abstract][Full Text] [Related]
10. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
11. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
12. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
[TBL] [Abstract][Full Text] [Related]
13. Effect of Immune-Related Adverse Events and Pneumonitis on Prognosis in Advanced Non-Small Cell Lung Cancer: A Comprehensive Systematic Review and Meta-analysis.
Li Y; Zhang Y; Jia X; Jiang P; Mao Z; Liang T; Du Y; Zhang J; Zhang G; Niu G; Guo H
Clin Lung Cancer; 2021 Nov; 22(6):e889-e900. PubMed ID: 34183265
[TBL] [Abstract][Full Text] [Related]
14. Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis.
Fan Y; Xie W; Huang H; Wang Y; Li G; Geng Y; Hao Y; Zhang Z
Front Oncol; 2021; 11():633032. PubMed ID: 33912454
[TBL] [Abstract][Full Text] [Related]
15. Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis.
Zhang Q; Wang W; Yuan Q; Li L; Wang YC; Chi CZ; Xu CH
Cancer Chemother Pharmacol; 2022 Jan; 89(1):1-9. PubMed ID: 34821962
[TBL] [Abstract][Full Text] [Related]
16. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
Front Immunol; 2021; 12():760737. PubMed ID: 34925331
[TBL] [Abstract][Full Text] [Related]
17. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
[TBL] [Abstract][Full Text] [Related]
18. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
[TBL] [Abstract][Full Text] [Related]
19. Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer.
Qin W; Yang L; Fan B; Zou B; Duan Y; Li B; Wang L
Front Immunol; 2022; 13():931429. PubMed ID: 36248782
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.
Yu Y; Zhou Y; Zhang X; Tan K; Zheng J; Li J; Cui H
Front Oncol; 2022; 12():934093. PubMed ID: 35912183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
